Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe ...
Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster ...
(RTTNews) - Alumis Inc. (ALMS) announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...
The MarketWatch News Department was not involved in the creation of this content. MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to 20% Average Weight Loss ...
LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...
Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH December 19, 2025 8:00 AM ...
The Times of Israel on MSN
Witkoff says talks on 2nd phase of ceasefire to continue this week: ‘Phase two is absolutely going to begin’
Steve Witkoff, US President Donald Trump’s special envoy to the Middle East, says that talks on phase two of the hostage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback